New strategies in the secondary prevention of relapsing venous thromboembolism;Nuevas estrategias en la prevención secundaria de la recurrencia de la tromboembolia venosa

Medicina Clinica

Volumn 125, Issue 19, 2005, Pages 748-755

  Lecumberri, Ramón ^a   Feliu, Jesús ^a   Rocha, Eduardo ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Low molecular weight heparin; Oral anticoagulants; Secondary prophylaxis; Venous thromboembolism

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; BEMIPARIN; DALTEPARIN; ENOXAPARIN; HEPARIN; IDRAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; TINZAPARIN; WARFARIN; XIMELAGATRAN;

BLEEDING; CLINICAL TRIAL; HUMAN; LOW DRUG DOSE; PROPHYLAXIS; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; SIDE EFFECT; VENOUS THROMBOEMBOLISM;

EID: 29444452559     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-7753(05)72176-x     Document Type: Review

References (42)

1. Rocha E, Panizo C, Lecumberri R. Tratamiento de la enfermedad tromboembólica venosa. Med Clin (Barc). 2000;115:224-35.
2. Rocha E, Panizo C, Lecumberri R, Aranguren A, Cuesta B, Hermida J. Tratamiento de la tromboembolia pulmonar. Med Clin (Barc). 2002;3 Supl 2:46-53.
3. Coon WW, Willis PW. Recurrence of venous thromboembolism. Surgery. 1973;73:823-7.
4. Research Committee of the British Thoracic Society. Optimal duration of anticoagulation for deep vein thrombosis and pulmonary embolism. Lancet. 1992;340:873-6.
5. Prandoni P, Lensing AW, Büller HR, Cogo A, Prins MH, Cattelan AM, et al. Deep vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med. 1992;327:1128-33.
6. Schulman S, Rhedin AS, Lindmarker P, Carlson A, Larfars G, Nicol P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med. 1995;332:1661-5.
7. Levine MN, Hirsh J, Gent M, Turpie AG, Weitz J, Ginsberg J, et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost. 1995;74:606-11.
8. Kearon C, Gent M, Hirsh J, Weitz J, Kovacs M, Anderson DR, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med. 1999;340:901-7.
9. Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Iorio A, Bazzan M, et al, for the Warfarin Optimal Duration Italian Trial Investigators. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med. 2001;345:165-9.
10. Pinede L, Ninet J, Duhaut P, Chabaud S, Demolombe-Rague S, Durieu I, et al, for the Investigators of the «Durée Optimale Traitement antiVitamines K» (DOTAVK) Study. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation. 2001;103:2453-60.
11. Schulman S, Granqvist S, Holmström M, Carlsson A, Lindmarker P, Nicol P, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med. 1997;336:393-8.
12. Pinede L, Duhaut P, Cucherat M, Ninet J, Pasquier J, Boissel JP. Comparison of log versus short duration of anticoagulant therapy after a first episode of venous thromboembolism: a meta-analysis of randomized, controlled trials. J Intern Med. 2000;247:553-62.
13. Prins MH, Hutten BA, Koopman MMW, Büller HR. Long-term treatment of venous thromboembolic disease. Thromb Haemost. 1999;82:892-8.
14. Van Dongen CJ, Vink R, Hutten BA, Buller HR, Prins MH. The incidence of recurrent venous thromboembolism after treatment with vitamin K antagonists in relation to time since first event: a meta-analysis. Arch Intern Med. 2003;163:1285-93.
15. Buller HR, Prins MH. Secondary prophylaxis with warfarina for venous thromboembolism. N Engl J Med. 2003;349:702-4.
16. Kearon C, Gonsberg JS, Anderson DR, Kovacs MJ, Wells P, Julian JA, et al, for the SOFAST Investigators. Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. J Thromb Haemost. 2004;2:743-9.
17. Hull R, Hirsh J, Jay R, Carter C, England C, Gent M, et al. Different intensities of oral anticoagulant therapy in the treatment of proximal vein thrombosis. N Engl J Med. 1982;307:1676-81.
18. Klein KL, Berdeaux DH, Milhollen JD, Hilden JT, Obernuefemann NJ, Koch MA, et al. Equal effectiveness of very-low-intensity anticoagulation and standard low-intensity anticoagulation: a pilot study. South Med J. 1995;88:1136-9.
19. Svenson P, Södermark A, Schulman S. Experiences of a low-intensity anticoagulation regimen for extended secondary prevention of venous thromboembolism. Haematol J. 2002;3:311-4.
20. Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Eby CS, Deitcher SR, et al, for the PREVENT Investigators. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med. 2003;348:1425-34.
21. Kearon C, Ginsberg JS, Kovacs MJ, Anderson DR, Wells P, Julian JA, et al, for the Extended Low-intensity Anticoagulation for Thromb-Embolism Investigators. Comparison of low-intensity warfarin therapy with conventional-intensity warfarina therapy for long-term prevention of recurrent thromboembolism. N Engl J Med. 2003;349:631-9.
22. Pini M, Aiello S, Manotti C, Pattacini C, Quintavalla R, Poli T, et al. Low-molecular-weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost. 1994;72:191-7.
23. Monreal M, Lafoz E, Olive A, Del Río L, Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost. 1994;71:7-11.
24. Das SK, Cohen AT, Edmondson RA, Melissari E, Kakkar VV. Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World J Surg. 1996;20:521-7.
25. Lopaciuk S, Bielska-Falda H, Nosczyk W, Bielwiec M, Witkiewicz W, Filipecki S, et al. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thromb Haemost. 1999;81:26-31.
26. Gonzales-Fajardo JA, Arreba E, Castrodeza J, Pérez JL, Fernández L, Agúndez I, et al. Venographic comparison of subcutaneous low molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis. J Vasc Surg. 1999;30:283-92.
27. Veiga F, Escribá A, Maluenda MP, López Rubio M, Margalet I, Lezana A, et al. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the log-term treatment of deep venous thrombosis in the elderly: a randomized trial. Thromb Haemost. 2000;84:559-64.
28. López-Beret P, Orgaz A, Fontcuberta J, Doblas M, Martínez RVT, Lozano G, et al. Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis. J Vasc Surg. 2001;33:77-90.
29. Hull RD, Pineo GF, Mah AF, Brant RF, for the LITE Study Investigators. Home-lite: safety and efficacy results for a study investigating the long term out-of-hospital treatment of patients with proximal venous thrombosis using subcutaneous low-molecular-weight heparin versus warfarin [resumen]. Thromb Haemost. 2001;Suppl:OC1647.
30. Kakkar VV, Gebska M, Kadziola Z, Roach C, Saba N, Carrasco P, on behalf of the Bemiparin Investigators. Low-molecular-weight heparin in the acute and long-term, treatment of deep vein thrombosis. Thromb Haemost. 2003;89:674-80.
31. Beckman JA, Dunn K, Sasahara AA, Goldhaber SZ. Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism. Thromb Haemost. 2003;89:953-8.
32. Marchetti M, Pistorio A, Barone M, Serafini S, Barosi G. Low molecular weight heparin versus warfarina for secondary prophylaxis of venous thromboembolism: a cost-effectiveness analysis. Am J Med. 2001;111:130-9.
33. Iorio A, Guercini F, Pini M. Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants. J Thromb Haemost. 2003;1:1906-13.
34. Greer IA, Nelson-Piercy C. Low-molecular-wight heparin for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood. 2005;106:401-7.
35. Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer. A randomized controlled study. Arch Intern Med. 2002;162:1729-35.
36. Lee AYY, Levine MN, Baker RI, Bowden C, Kakkar AJ, Prins M, et al, for the Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146-53.
37. Hull R, Pineo GF, Mah AF, Brant RF for the LITE Investigators. A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months vs. intravenous heparin followed by warfarina sodium in patients with current cancer [resumen]. J Thromb Haemost. 2003;1:P 373.
38. Deitcher SR, Kessler CM, Merli G, Rigas J, Lyons RM, Cort S. Secondary prevention of venous thromboembolic events (VTE) in patients with active malignancy: a randomized study of enoxaparina sodium alone vs. initial enoxaparina sodium followed by warfarina for a 180-day period [resumen]. J Thromb Haemost. 2003;1:OC194.
39. Monreal M, Zacharski L, Jiménez JA, Roncalés J, Vilaseca B. Fixed-dose low-molecular-weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer: a prospective cohort study. J Thromb Haemost. 2004;2:1311-5.
40. The PERSIST Investigators. A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarina for secondary prevention in deep vein thrombosis. A phase II evaluation. J Thromb Haemost. 2004;2:47-53.
41. Schulman S, Wählanbder K, Lundström T, Clason SB, Eriksson H, for the THRIVE III Investigators. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med. 2003;349:1713-21.
42. Fiessinger JN, Huisman MV, Davidson BL, Bounameaux H, Francis CW, Eriksson H, et al, for the THRIVE Treatment Study investigators. Ximelagatran vs low-molecular-weight heparin and warfarina for the treatment of deep vein thrombosis. JAMA. 2005;293:681-9.